Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Verheyen

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 18, 2016
Erratum to: Treatment costs of attention deficit hyperactivity disorder in GermanySebastian Braun, Jan Zeidler, Roland Linder, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|June 25, 2015
[Stepwise Diagnostics, Federal Joint Committee Directive and Actual Care in the Case of Sleep-related Breathing Disorders - An Analysis Based on Claims Data of the Techniker Krankenkasse]Udo Schneider, Roland Linder, Ernst-Günther Hagenmeyer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 27, 2012
Treatment costs of attention deficit hyperactivity disorder in GermanySebastian Braun, Jan Zeidler, Roland Linder, et al.
Journal of Diabetes and Its Complications|June 2, 2016
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase studyDirk Enders, Bianca Kollhorst, Susanne Engel, et al.
Rheumatology (Oxford, England)|August 18, 2022
Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world settingBenjamin Birkner, Jürgen Rech, Edmund Edelmann, et al.
Zeitschrift Fur Rheumatologie|June 23, 2023
Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritisBenjamin Birkner, Jürgen Rech, Edmund Edelmann, et al.
Orphanet Journal of Rare Diseases|February 22, 2013
Cost of illness and economic burden of chronic lymphocytic leukemiaCarl Rudolf Blankart, Taika Koch, Roland Linder, et al.
BMC Musculoskeletal Disorders|November 20, 2012
Replacement of endoprosthetic implants within a two years follow-up period: a statutory health insurance routine data analysisRoland Linder, Hardy Müller, Brigitte Grenz-Farenholtz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 21, 2012
How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitusThomas Wilke, Antje Groth, Sabrina Mueller, et al.
Community Dentistry and Oral Epidemiology|April 23, 2015
Informed consumer or unlucky visitor? A profile of German patients who received dental services abroadDimitra Panteli, Uta Augustin, Julia Röttger, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 18, 2016
Erratum to: Treatment costs of attention deficit hyperactivity disorder in GermanySebastian Braun, Jan Zeidler, Roland Linder, et al.
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|June 25, 2015
[Stepwise Diagnostics, Federal Joint Committee Directive and Actual Care in the Case of Sleep-related Breathing Disorders - An Analysis Based on Claims Data of the Techniker Krankenkasse]Udo Schneider, Roland Linder, Ernst-Günther Hagenmeyer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|November 27, 2012
Treatment costs of attention deficit hyperactivity disorder in GermanySebastian Braun, Jan Zeidler, Roland Linder, et al.
Journal of Diabetes and Its Complications|June 2, 2016
Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase studyDirk Enders, Bianca Kollhorst, Susanne Engel, et al.
Rheumatology (Oxford, England)|August 18, 2022
Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world settingBenjamin Birkner, Jürgen Rech, Edmund Edelmann, et al.
Zeitschrift Fur Rheumatologie|June 23, 2023
Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritisBenjamin Birkner, Jürgen Rech, Edmund Edelmann, et al.
Orphanet Journal of Rare Diseases|February 22, 2013
Cost of illness and economic burden of chronic lymphocytic leukemiaCarl Rudolf Blankart, Taika Koch, Roland Linder, et al.
BMC Musculoskeletal Disorders|November 20, 2012
Replacement of endoprosthetic implants within a two years follow-up period: a statutory health insurance routine data analysisRoland Linder, Hardy Müller, Brigitte Grenz-Farenholtz, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 21, 2012
How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitusThomas Wilke, Antje Groth, Sabrina Mueller, et al.
Community Dentistry and Oral Epidemiology|April 23, 2015
Informed consumer or unlucky visitor? A profile of German patients who received dental services abroadDimitra Panteli, Uta Augustin, Julia Röttger, et al.
Pageof 4